Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 6,517 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Cavity Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

NCT05803850
View directory record Official record
Conditions
IPF
Interventions
HNC1058 Capsules
Drug
Lead sponsor
Guangzhou Henovcom Bioscience Co. Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Polypodium Leucotomos for Melasma

NCT01162850
View directory record Official record
Conditions
Melasma
Interventions
Polypodium Leucotomos, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 26, 2026, 6:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Trial to Compare the Effects of Myo Munchee Therapy and Oral Motor Therapy (OMT) in Pediatric Patients to Treat Maxillary Deficiency and Orofacial Myofunctional Dysfunction (OMD).

NCT07088055
View directory record Official record
Conditions
Orofacial Myofunctional Disorders, Myo Munchee, Oral Motor Therapy, Maxillary Deficiency
Interventions
Chewing device only, Myo Munchee and Oral Motor Therapy Treatment, Oral Motor Therapy Treatment Arm
Device · Other
Lead sponsor
Myo Munchee (Operations) Pty Ltd
Industry
Eligibility
3 Years to 5 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 26, 2026, 6:45 PM EDT
Terminated Phase 1 Interventional

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

NCT04241835
View directory record Official record
Conditions
Hepatic Impairment, Advanced Malignant Solid Tumor
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Lake Mary, Florida • Chicago, Illinois • Royal Oak, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

NCT00478725
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034, oral, GW786034, IV, GW786034, radiolabeled oral
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

NCT03472040
View directory record Official record
Conditions
Hereditary Angioedema, HAE, Prophylaxis
Interventions
BCX7353
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 26, 2026, 6:45 PM EDT
Completed No phase listed Observational

Gut Microbiome in Colorectal Cancer

NCT04054908
View directory record Official record
Conditions
Gastrointestinal Microbiome, Neoplasm, Colorectal
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Results available

Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty

NCT02839876
View directory record Official record
Conditions
Osteoarthritis, Acetaminophen, Arthroplasty, Hip Replacement
Interventions
Intravenous acetaminophen, Oral acetaminophen
Drug
Lead sponsor
Duke University
Other
Eligibility
56 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

NCT00560417
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Lispro Protamine Suspension, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
49
States / cities
Phoenix, Arizona • Concord, California • Escondido, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2011 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

NCT02576717
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
2,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Berkeley, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

NCT04228302
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral capsule, Placebo oral capsule
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 26, 2026, 6:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

NCT02581137
View directory record Official record
Conditions
Erythroplakia, Hyperplasia, Oral Cavity Carcinoma, Oral Leukoplakia
Interventions
Laboratory Biomarker Analysis, Metformin Hydrochloride
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
San Diego, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

NCT02672839
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
LGD-6972 Solution, LGD-6972 Capsules
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 26, 2026, 6:45 PM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681
View directory record Official record
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS

NCT00000981
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Fiacitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

NCT00796965
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD7268, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Oct 26, 2026, 6:45 PM EDT
Terminated Phase 2 Interventional Results available

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

NCT01682031
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Xerostomia
Interventions
selenomethionine, placebo, cisplatin, radiation therapy, quality-of-life assessment
Dietary Supplement · Other · Drug + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)

NCT01911637
View directory record Official record
Conditions
Healthy
Interventions
VBY-036, Placebo
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy

NCT02229539
View directory record Official record
Conditions
Acute Oral Mucositis Pain
Interventions
doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
350
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 221 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Early Phase 1 Interventional Results available

A Dose-Finding Study of AG-348 in Sickle Cell Disease

NCT04000165
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
AG-348
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

A Study of Peldesine (BCX-34) in HIV-Infected Patients

NCT00002237
View directory record Official record
Conditions
HIV Infections
Interventions
Peldesine
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 6:45 PM EDT
Terminated Not applicable Interventional

Effect of Oral Appliance Therapy on Atrial Fibrillation

NCT03835429
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
MyTAP oral appliance plus mouth shield
Device
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 26, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

NCT01005472
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
sunitinib malate, temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 26, 2026, 6:45 PM EDT